Quest Diagnostics Incorporated DGX NYSE

Quest Diagnostics Incorporated (DGX) reported total assets of $16.23B and total liabilities of $8.94B for fiscal year 2025, resulting in total equity of $7.29B.

The company held $420M in cash and short-term investments. Total debt stood at $6.92B, with net debt of $6.5B. The Debt-to-Equity (D/E) ratio was 0.95 (moderate).

Current ratio is 1.04, suggesting adequate short-term liquidity. Interest coverage is 6.1x (adequate).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (61/100) — Total assets $16.23B and equity $7.29B support the company's competitive scale
• VALUE (44/100) — Debt-to-Equity 0.95 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 55/100 with 1/7 criteria passed.

IDXX

IDEXX Laboratories, Inc.

$584.05

+1.75%

A

Agilent Technologies, Inc.

$120.40

+2.47%

IQV

IQVIA Holdings Inc.

$175.28

+1.91%

MTD

Mettler-Toledo International Inc.

$1,341.53

-0.32%

UTHR

United Therapeutics Corporation

$578.54

+0.16%

LH

Labcorp Holdings Inc.

$268.87

+1.78%

ILMN

Illumina, Inc.

$130.32

+2.65%

WAT

Waters Corporation

$330.98

+1.94%